Navigation Links
DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results
Date:11/8/2007

CLEVELAND, Nov. 8 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (Nasdaq: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today reported its operating results for the third quarter and first nine months of 2007.

For the three months ended September 30, 2007, revenue decreased 52% to $2,116,000, and the Company reported a net loss of $(3,506,000), or $(0.26) per share on a basic and diluted basis. These results compared with revenue of $4,374,000, and a net loss of $(1,326,000), or $(0.12) per share basic and diluted basis, in the third quarter of 2006.

For the nine months ended September 30, 2007, DATATRAK's revenue decreased 36% to $8,723,000, and a net loss of $(8,367,000), or $(0.64) per share on a basic and diluted basis was recorded for the period. The Company reported revenue of $13,705,000, and a net loss of $(2,109,000), or $(0.19) per share basic and diluted basis, in the corresponding period of the previous year.

During the three months ended September 30, 2007, the Company recorded an impairment charge of $213,000 against its non-compete intangible asset acquired from ClickFind.

DATATRAK recorded severance charges totaling $386,000 in the third quarter of 2007 associated with the net reduction of 11 employees. The employee reductions are expected to decrease annual direct costs by approximately $280,000 and annual SG&A expenses by approximately $520,000, for a total cost reduction of approximately $800,000 per year. Coupled with the 17 employee reductions from earlier in the year, annual direct costs are expected to decrease by approximately $795,000 and annual SG&A expenses are expected to decrease by approximately $1,395,000 in future years.

The gross profit margin for the third quarter was 50% compared to 70% the same period a year ago. The decline in gross profit margin continues to be mostly the result of a significant decrease in revenue offset to some degree by a 20% reduction in direct costs.

DATATRAK's backlog at September 30, 2007 was $10.7 million and backlog currently stands at approximately $11.6 million. This compares to a backlog of $12.2 million at December 31, 2006. Backlog is defined as the remaining value of signed contracts or authorization letters to commence services. The Company does not include in its backlog potential contracts or authorization letters that have passed the verbal stage, but have not been signed. All contracts are subject to possible delays or cancellation or can change in scope in a positive or negative direction. Therefore, current backlog is not necessarily indicative of the Company's future quarterly or annual revenue. Historically, backlog has been a poor predictor of the Company's short-term revenue.

"During the third quarter, we have made significant progress in the reorganization of our global marketing and sales efforts by adding key individuals in the United States and Europe with extensive experience in the clinical trials market," stated Dr. Jeffrey A. Green, President and Chief Executive Officer of DATATRAK International, Inc. "We are starting to see early positive signs of these efforts through new projects and new client relationships, though several of these new projects are not yet reflected in backlog because of signature timing. We are also seeing increasing demand for our consulting efforts as a growing number of clients on a global scale will be requiring training for Enterprise Transfer so that they can learn how to implement clinical trials independently with our eClinical Platform."

Green continued, "We are continuing to evaluate and modify our cost structure to be consistent with our current business flow and to conserve cash resources, while being careful not to adversely affect our ability to deliver on the many opportunities we see developing over the next several months and into 2008. Our software development efforts have continued and are focused on advancements that are requested by clients through our Product Advisory Council which will directly lead to new and innovative revenue opportunities for our product suite moving forward. We believe that there are several significant instances where global clients are openly not satisfied with their current clinical trials technology provider where we can capitalize on these opportunities because of our software development advancements over the past year. Our nearer term objectives are to deliver substantiated signs of progress from a combination of new and expanded customer relationships and a broader global footprint throughout the remainder of 2007. In time, successful execution of these objectives together with our refined cost structure should translate into backlog, revenue and earnings growth."

The Company will also host a conference call today at 4:30 p.m. ET. To participate via phone, participants are asked to dial 412-858-4600 a few minutes before 4:30 p.m. ET. The conference call will also be available via live web cast on DATATRAK International, Inc.'s web site by clicking the button labeled "Click here for Live Web Cast, 3rd Quarter Earnings Call" on the Company's homepage at http://www.datatrak.net a few minutes before 4:30 p.m. ET.

A replay of the phone call and web cast will each be available at approximately 6:30 p.m. ET on November 8, 2007 and will run until 9:00 a.m. ET on November 15, 2007. The phone replay can be accessed by dialing 412-317-0088 (access code 412002). To access the web cast replay go to the Company's homepage at http://www.datatrak.net and click the button labeled "Click here for Replay of Web Cast, 3rd Quarter Earnings Call".

DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 17 drugs and devices that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, Bonn, Germany, and Bryan, Texas. Its common stock is listed on the NASDAQ Stock Market under the ticker symbol "DATA". Visit the DATATRAK International, Inc. web site at http://www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations and beliefs concerning future events impacting the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the Company's success in integrating its acquisition's operations into its own operations and the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement.

DATATRAK International, Inc. and Subsidiaries

Condensed Consolidated Balance Sheet Data

(Unaudited)

September 30, 2007 December 31, 2006

Cash and investments $8,677,220 $5,015,577

Accounts receivable, net 1,478,417 2,226,317

Deferred tax asset 1,233,400 1,858,800

Property and equipment, net 3,881,371 4,736,233

Goodwill 10,863,383 10,863,383

Other intangible assets, net 707,107 1,914,206

Other 665,236 605,666

Total assets $27,506,134 $27,220,182

Accounts payable and other current

liabilities $4,159,666 $3,709,485

Long-term liabilities 4,419,949 5,446,703

Shareholders' equity 18,926,519 18,063,994

Total liabilities and shareholders'

equity $27,506,134 $27,220,182

DATATRAK International, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

For the Three Months Ended

September 30,

2007 2006

Revenue $2,116,333 $4,374,360

Direct costs 1,061,088 1,327,173

Gross profit 1,055,245 3,047,187

Selling, general and administrative

expenses 3,282,508 3,391,522

Severance expense 386,368 ---

Depreciation and amortization 669,941 628,648

Impairment loss 213,209 ---

Loss from operations (3,496,781) (972,983)

Interest income 128,623 50,047

Interest expense (91,121) (106,208)

Loss before income taxes (3,459,279) (1,029,144)

Income tax expense 47,000 297,000

Net loss $(3,506,279) $(1,326,144)

Net loss per share:

Basic:

Net loss per share $(0.26) $(0.12)

Weighted-average shares

outstanding 13,634,075 11,400,675

Diluted:

Net loss per share $(0.26) $(0.12)

Weighted-average shares

outstanding 13,634,075 11,400,675

DATATRAK International, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

For the Nine Months Ended

September 30,

2007 2006

Revenue $8,723,138 $13,704,673

Direct costs 3,617,858 3,877,047

Gross profit 5,105,280 9,827,626

Selling, general and administrative

expenses 10,326,314 9,911,092

Severance expense 723,429 294,974

Depreciation and amortization 2,178,986 1,663,692

Impairment loss 213,209 ---

Loss from operations (8,336,658) (2,042,132)

Interest income 350,328 181,416

Interest expense (285,616) (248,088)

Other expense (1,700) ---

Loss before income taxes (8,273,646) (2,108,804)

Income tax expense 93,600 ---

Net loss $(8,367,246) $(2,108,804)

Net loss per share:

Basic:

Net loss per share $(0.64) $(0.19)

Weighted-average shares

outstanding 13,014,534 11,205,113

Diluted:

Net loss per share $(0.64) $(0.19)

Weighted-average shares

outstanding 13,014,534 11,205,113


'/>"/>
SOURCE DATATRAK International, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. DATATRAK International Management To Host Conference Call on November 8, 2007 To Discuss Third Quarter and Nine Month Operating Results for 2007
2. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
3. Arrow International, Inc. Invites You to Join Its 2007 Annual Meeting of Shareholders on the Web
4. Natural Alternatives International, Inc. Announces Late Filing of its Annual Report on Form 10-K, Revenue for Fiscal 2007 and Guidance on First Quarter of Fiscal 2008
5. Cryo-Cell International, Inc. Reports Third Quarter 2007 Results
6. TenderCare International, Inc. Announces Signing of Merger Agreement with the Hain Celestial Group for All Outstanding Shares of TenderCare Stock
7. Chindex International, Inc. Announces Results for the Quarter and Six Months Ended September 30, 2007
8. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
9. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
10. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
11. HEI, Inc. Announces Sale of RFID Division Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... CastCoverz!, America’s #1 trusted brand ... country's oldest waterproof cast protector . As the largest one-stop, orthopedic shop, ... of daily, night, weatherproof and waterproof covers for most orthopedic devices, including but ...
(Date:4/28/2016)... ... ... University of New England President Danielle N. Ripich is pleased to announce ... In addition to his role as director of Athletics, McDonald will oversee a ... space of just one year Jack has distinguished himself by his commitment to our ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... the organization’s most successful events, attracting medical professionals from around the globe who ... networking events. , Opening Ceremonies Sunday, April 17 included the introduction of the ...
(Date:4/28/2016)... ... April 28, 2016 , ... Trinity Health, one of ... leading force in the fight to reduce tobacco use and its deadly toll, ... help reduce tobacco use. The initiative brings together two organizations committed to achieving ...
(Date:4/28/2016)... ... April 28, 2016 , ... In many parts of the world, contamination ... mortality. This is particularly true in underdeveloped parts of Africa where clean sources of ... England’s campus in Tangier, Morocco, will examine this global health issue and consider how ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... New York , April 27, 2016 ... market report titled, "Skincare Devices Market - Global Industry ... 2023." According to the report, the global skincare devices ... and is anticipated to expand at a CAGR of ... Mn in 2023. Browse the full Skincare Devices ...
(Date:4/27/2016)... Research and Markets has ... Disposables Market 2016-2020"  report to their offering.  ... global anesthesia disposables market is set to ... the period 2016-2020.  Healthcare-acquired infections ... safety. Organizations like the CDC and Public ...
(Date:4/26/2016)... 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) is ... , Pharm D., to Vice President of Education and ... Hagerman will continue to lead and oversee Diplomat University, ... education and training to Diplomat employees and external professionals ... University also houses the quality assurance department, which focuses ...
Breaking Medicine Technology: